ConductScience.org, home
Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia
API referenceFor AI assistants

Trial · NCT04659863

Registered outcomes22

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 20 of 22

Download this page as JSON
ListOutcomeTime frameDescription
PrimaryPercentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1)Baseline and Day 330Percentage change in low-density lipoprotein cholesterol (LDL-C) from baseline to Day 330 (Year 1)
SecondaryTime-adjusted Percent Change in LDL-C From Baseline After Day 90 and up to Day 330 (Part 1/Year 1)Baseline, after Day 90 up to Day 330Time-adjusted percent change in LDL-C (after Day 90 and up to Day 330), calculated as the average of percent changes from baseline to Days 150, 270 and 330
SecondaryPercent Change in LDL-C From Baseline up to Day 720Baseline, up to Day 720Percentage change in LDL-C from baseline to each assessment time up to Day 720.
SecondaryAbsolute Change in LDL-C From Baseline up to Day 720Baseline, up to Day 720Absolute change in LDL-C from baseline to each assessment time up to Day 720.
SecondaryPercent Change in Apo B From Baseline up to Day 720Baseline, up to Day 720Percentage change in apolipoprotein B (Apo B) from baseline to each assessment time up to Day 720.
SecondaryAbsolute Change in Apo B From Baseline up to Day 720Baseline, up to Day 720Absolute change in apolipoprotein B (Apo B) from baseline to each assessment time up to Day 720.
SecondaryPercent Change in Lp(a) From Baseline up to Day 720Baseline, up to Day 720Percentage change in lipoprotein (a) \[Lp(a)\] from baseline to each assessment time up to Day 720.
SecondaryAbsolute Change in Lp(a) From Baseline up to Day 720Baseline, up to Day 720Absolute change in lipoprotein (a) \[Lp(a)\] from baseline to each assessment time up to Day 720.
SecondaryPercent Change in Non-HDL-C From Baseline up to Day 720Baseline, up to Day 720Percentage change in non-high density lipoprotein cholesterol (non-HDL-C) from baseline to each assessment time up to Day 720.
SecondaryAbsolute Change in Non-HDL-C From Baseline up to Day 720Baseline, up to Day 720Absolute change in non-high density lipoprotein cholesterol (non-HDL-C) from baseline to each assessment time up to Day 720.
SecondaryPercent Change in Total Cholesterol From Baseline up to Day 720Baseline, up to Day 720Percentage change in total cholesterol from baseline to each assessment time up to Day 720.
SecondaryAbsolute Change in Total Cholesterol From Baseline up to Day 720Baseline, up to Day 720Absolute change in total cholesterol from baseline to each assessment time up to Day 720.
SecondaryPercent Change in Triglycerides From Baseline up to Day 720Baseline, up to Day 720Percentage change in triglycerides from baseline to each assessment time up to Day 720.
SecondaryAbsolute Change in Triglycerides From Baseline up to Day 720Baseline, up to Day 720Absolute change in triglycerides from baseline to each assessment time up to Day 720.
SecondaryPercent Change in HDL-C From Baseline up to Day 720Baseline, up to Day 720Percentage change in high density lipoprotein cholesterol (HDL-C) from baseline to each assessment time up to Day 720.
SecondaryAbsolute Change in HDL-C From Baseline up to Day 720Baseline, up to Day 720Absolute change in high density lipoprotein cholesterol (HDL-C) from baseline to each assessment time up to Day 720.
SecondaryPercent Change in VLDL-C From Baseline up to Day 720Baseline, up to Day 720Percentage change in very low density lipoprotein cholesterol (VLDL-C) from baseline to each assessment time up to Day 720.
SecondaryAbsolut Change in VLDL-C From Baseline up to Day 720Baseline, up to Day 720Absolute change in very low density lipoprotein cholesterol (VLDL-C) from baseline to each assessment time up to Day 720.
SecondaryPercent Change in Apo A1 From Baseline up to Day 720Baseline, up to Day 720Percentage change in apolipoprotein A1 (Apo A1) from baseline to each assessment time up to Day 720.
SecondaryAbsolute Change in Apo A1 From Baseline up to Day 720Baseline, up to Day 720Absolute change in apolipoprotein A1 (Apo A1) from baseline to each assessment time up to Day 720.

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04659863/registered

API referenceFor AI assistants